
IgG4-Related Disease - Pipeline Insight, 2025
Description
DelveInsight’s, “IgG4-Related Disease - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in IgG4-Related Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
IgG4-Related Disease: Overview
IgG4 Related Disease (IgG4-RD) is a systemic fibroinflammatory disease characterized by dense infiltration of IgG4-positive plasma cells in the affected tissue(s) with or without elevated plasma levels of IgG4. It is a chronic-fibroinflammatory disorder affecting a wide range of organs. Elevation of serum IgG4 concentrations and abundant infiltration of IgG4-expressing plasma cells are key diagnostic features of this autoimmune disease. IgG4RD may be present in a certain proportion of patients with a wide variety of diseases, including Mikulicz’s disease, autoimmune pancreatitis, hypophysitis, Riedel thyroiditis, interstitial pneumonitis, interstitial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pseudotumor.
The signs and symptoms of the IgG4-related disease vary based on the organ that gets affected, such as pancreas, bile ducts, gallbladder, liver, thyroid gland, salivary and lacrimal glands, orbits, retroperitoneal fibrosis and large vessel involvement, intrapulmonary, mediastinal and pleural involvement, lymph nodes and kidney. While the most characteristic clinical sign of IgG4-related disease includes obstructive jaundice in the patients. There are also several clinical manifestations involved with the IgG4-RD, which include Lymphadenopathy, Autoimmune pancreatitis, IgG4-related sclerosing cholangitis, etc.
The diagnosis of IgG4-RD generally requires piecing together clues from several areas:
There are no specific drugs available that cure the disease completely as the pathophysiology of the IgG4 related disease is not clear and still under research and development. Currently, the market holds no approved therapies for patients with IgG4-related diseases. According to the recent guidelines published by “International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease,” which explained the criteria for determining the type of disease caused due to IgG4 levels and the treatment guidelines for the patients. The commonly used treatment options include Glucocorticoids, Immunomodulators, and Rituximab. Conventional “Disease-Modifying Anti-Rheumatic Drugs” (DMARDs) in IgG4-RD is also used for the treatment in specific cases.
""IgG4-Related Disease - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IgG4-Related Disease pipeline landscape is provided which includes the disease overview and IgG4-Related Disease treatment guidelines. The assessment part of the report embraces, in depth IgG4-Related Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgG4-Related Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the IgG4-Related Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IgG4-Related Disease Emerging Drugs
Further product details are provided in the report……..
IgG4-Related Disease: Therapeutic Assessment
This segment of the report provides insights about the different IgG4-Related Disease drugs segregated based on following parameters that define the scope of the report, such as:
IgG4-Related Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IgG4-Related Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgG4-Related Disease drugs.
IgG4-Related Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
IgG4-Related Disease: Overview
IgG4 Related Disease (IgG4-RD) is a systemic fibroinflammatory disease characterized by dense infiltration of IgG4-positive plasma cells in the affected tissue(s) with or without elevated plasma levels of IgG4. It is a chronic-fibroinflammatory disorder affecting a wide range of organs. Elevation of serum IgG4 concentrations and abundant infiltration of IgG4-expressing plasma cells are key diagnostic features of this autoimmune disease. IgG4RD may be present in a certain proportion of patients with a wide variety of diseases, including Mikulicz’s disease, autoimmune pancreatitis, hypophysitis, Riedel thyroiditis, interstitial pneumonitis, interstitial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pseudotumor.
The signs and symptoms of the IgG4-related disease vary based on the organ that gets affected, such as pancreas, bile ducts, gallbladder, liver, thyroid gland, salivary and lacrimal glands, orbits, retroperitoneal fibrosis and large vessel involvement, intrapulmonary, mediastinal and pleural involvement, lymph nodes and kidney. While the most characteristic clinical sign of IgG4-related disease includes obstructive jaundice in the patients. There are also several clinical manifestations involved with the IgG4-RD, which include Lymphadenopathy, Autoimmune pancreatitis, IgG4-related sclerosing cholangitis, etc.
The diagnosis of IgG4-RD generally requires piecing together clues from several areas:
- Clinical findings
- Serological data
- Radiology studies
- Pathology results
There are no specific drugs available that cure the disease completely as the pathophysiology of the IgG4 related disease is not clear and still under research and development. Currently, the market holds no approved therapies for patients with IgG4-related diseases. According to the recent guidelines published by “International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease,” which explained the criteria for determining the type of disease caused due to IgG4 levels and the treatment guidelines for the patients. The commonly used treatment options include Glucocorticoids, Immunomodulators, and Rituximab. Conventional “Disease-Modifying Anti-Rheumatic Drugs” (DMARDs) in IgG4-RD is also used for the treatment in specific cases.
""IgG4-Related Disease - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IgG4-Related Disease pipeline landscape is provided which includes the disease overview and IgG4-Related Disease treatment guidelines. The assessment part of the report embraces, in depth IgG4-Related Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgG4-Related Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence IgG4-Related Disease R&D. The therapies under development are focused on novel approaches to treat/improve IgG4-Related Disease.
This segment of the IgG4-Related Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IgG4-Related Disease Emerging Drugs
- Inebilizumab: Amgen
- Rilzabrutinib: Sanofi
Further product details are provided in the report……..
IgG4-Related Disease: Therapeutic Assessment
This segment of the report provides insights about the different IgG4-Related Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in IgG4-Related Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
IgG4-Related Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IgG4-Related Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgG4-Related Disease drugs.
IgG4-Related Disease Report Insights
- IgG4-Related Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing IgG4-Related Disease drugs?
- How many IgG4-Related Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IgG4-Related Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IgG4-Related Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for IgG4-Related Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Amgen
- Sanofi
- Zenas Biopharma
- Bristol-Myers Squibb
- Inebilizumab
- Rilzabrutinib
- Obexelimab
- Abatacept
Table of Contents
60 Pages
- Introduction
- Executive Summary
- IgG4-Related Disease: Overview
- Causes
- Etiology
- Signs and Symptoms
- Disease Treatment/Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- IgG4-Related Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Inebilizumab: Amgen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Rilzabrutinib: Sanofi
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- IgG4-Related Disease Key Companies
- IgG4-Related Disease Key Products
- IgG4-Related Disease- Unmet Needs
- IgG4-Related Disease- Market Drivers and Barriers
- IgG4-Related Disease- Future Perspectives and Conclusion
- IgG4-Related Disease Analyst Views
- IgG4-Related Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.